Morphology Preservation and Biomolecule Stabilization Now Available in One Tissue System
PAXgene® Tissue System enables researchers to maximize use of precious samples
Venlo, The Netherlands -- Jan. 27, 2009 - An integrated laboratory system for sample fixation, stabilization and purification is now available from PreAnalytiX GmbH. With the PAXgene Tissue System, researchers can for the first time perform histology, immunohistochemistry and stabilized RNA, miRNA, and DNA extractions from one sample without worrying about a compromised workflow.
Research laboratories working with human and animal tissue are faced with the challenge of conducting a variety of analyses on limited sample materials. The recognized standard for preserving tissue morphology is FFPE (formalin fixation/paraffin embedding). However, while this method provides excellent results for morphological studies, it does not preserve biomolecules. As a result, the DNA, RNA and miRNA molecules degrade, preventing the complete analysis required. This is a necessity for applications such as case-controlled and population-based clinical studies, facilitating biomarker discovery and, ultimately, the development of diagnostics and therapeutics.
"Researchers say they need a system that not only fixes the tissue but prevents degradation of the biomolecules needed for molecular analysis," says Marie McCluskey, Global Product Manager for Pre-analytical Systems at QIAGEN. "The PAXgene Tissue System combines tissue fixation with nucleic acid stabilization, enabling researchers to get the most information from samples. For example, a biopsy sample can be assessed by a pathologist for morphology, then the same sample can be used for molecular analysis as well. The stabilized nucleic acids make it possible for researchers to get optimal morphology and molecular results from one sample."
The PAXgene Tissue system has two components - a tissue container and tissue kits. The dual-chambered container is pre-filled with two reagents: PAXgene Tissue Fix for fast penetration and fixation, and PAXgene Tissue Stabilizer for storage and transport. The fixation process uses a standard histocasette with a fixative that is an alternative to formalin and is stopped by transferring the sample into the stabilizer. Fixation time is standardized at 2-4 hours. The sample is stable in the PAXgene Tissue Stabilizer for transport and storage prior to processing. Tissue can then be paraffin embedded and processed in pathology workflows. After tissue has been stabilized in PAXgene tissue containers (and optionally paraffin embedded), RNA, miRNA and DNA can be purified using the PAXgene tissue kits.
"We are pleased to be able to bring the PAXgene Tissue System to the market," says Peer Schatz, CEO of QIAGEN. "We believe that the technology represents a true breakthrough and that it brings a very powerful solution to a great, previously unmet need. The primary users of this product will be pathologists, oncologists, pharma companies and biobanks. These professionals and organizations rely on us to help them maximize the use of their precious samples in research to make improvements in life possible."
The PAXgene Tissue System from PreAnalytiX is the newest addition sold in QIAGEN's suite of tissue management technologies. The suite includes integrated products that standardize all steps of the workflow, starting with archived or prospectively collected tissues and ending with data analysis. This ensures comparability and reproducibility of data from laboratory to laboratory.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,000 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.